BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/21/2015 1:38:00 PM | Browse: 267 | Download: 507
Publication Name World Journal of Hepatology
Manuscript ID 17205
Country of Manuscript Source Italy
2015-02-25 10:46
Peer-Review Started
2015-02-25 20:17
To Make the First Decision
2015-06-03 14:39
Return for Revision
2015-06-04 16:25
2015-06-15 15:54
Second Decision
2015-06-24 08:20
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2015-07-02 16:14
Articles in Press
2015-07-02 16:15
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-07-28 09:08
Publish the Manuscript Online
2015-08-21 13:37
ISSN 1948-5182 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Editorial
Article Title Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure
Manuscript Source Invited Manuscript
All Author List Marcello Maida, Massimo Iavarone, Maurizio Raineri, Calogero Cammà and Giuseppe Cabibbo
Funding Agency and Grant Number
Correspondence To Marcello Maida, MD, Section of Gas­troenterology, DIBIMIS, University of Palermo, P.zza delle Cliniche 2, 90127 Palermo, Italy. marcello.maida@unipa.it
Keywords Systemic therapies; Sorafenib; Barcelona Clinic Liver Cancer; Hepatocellular carcinoma
Core Tip Hepatocellular carcinoma (HCC) is the main cause of death in patients with cirrhosis with an increasing incidence worldwide. Sorafenib is the choice therapy for advanced HCC. Since then no other molecule has been registered as first-line therapy in this setting and one more vacuum arises from the absence of molecules registered as second-line therapy for patients who have failed Sorafenib. What are the reasons and what we should expect in the near future?
Publish Date 2015-08-21 13:37
Citation Maida M, Iavarone M, Raineri M, Cammà C, Cabibbo G. Second line systemic therapies for hepatocellular carcinoma: Reasons for the failure. World J Hepatol 2015; 7(17): 2053-2057
Url http://www.wjgnet.com/1948-5182/full/v7/i17/2053.htm
DOI http://dx.doi.org/10.4254/wjh.v7.i17.2053
Full Article (PDF) WJH-7-2053.pdf
Full Article (Word) WJH-7-2053.doc
Revised Manuscript 17205-Review.docx
Peer-review Report 17205-Peer-review(s).pdf
Answering Reviewers 17205-Answering reviewers.pdf
Scientific Misconduct Check 17205-Scientific misconduct check.pdf
Scientific Editor Work List 17205-Scientific editor work list.pdf
Audio Core Tip 17205-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 17205-Conflict-of-interest statement.pdf
Copyright License Agreement 17205-Copyright assignment.pdf